For the year ending 2025-12-31, NKTR had -$29,136K decrease in cash & cash equivalents over the period. -$208,682K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 55,232 |
| Cost of goods sold | 0 |
| Rezpegaldesleukin | 51,531 |
| NKTRTwo Five Five | 6,486 |
| NKTRZero One Six Five | 9,569 |
| Discovery Research And Other Programs | 1,833 |
| Clinical development, contract manufacturing and other third party costs | 69,419 |
| Employee costs | 46,003 |
| Facilities costs | 12,306 |
| Other operating costs | 44,727 |
| Other segment expenses | 22,879 |
| Gain on sale of the huntsville manufacturing facility | 0 |
| Total operating costs and expenses | 195,334 |
| Loss from operations | -140,102 |
| Non-cash interest expense on liabilities related to sales of future royalties | 26,184 |
| Interest income | 10,438 |
| Other income (expense), net | 361 |
| Total non-operating income (expense), net | -15,385 |
| Loss before benefit for income taxes and equity method investment | -155,487 |
| Benefit for income taxes | -138 |
| Loss before equity method investment | -155,349 |
| Loss from equity method investment | -8,727 |
| Net loss | -164,076 |
| Non-cash royalty revenue related to the sales of future royalties | 54,932 |
| Non-cash interest expense on liabilities related to sales of future royalties | 26,184 |
| Loss from equity method investment | -8,727 |
| Stock-based compensation | 12,649 |
| Depreciation and amortization | 1,026 |
| Impairment of right-of-use assets and property, plant and equipment | 4,441 |
| Gain on sale of the huntsville manufacturing facility | 0 |
| Provision for net realizable value of inventory | 0 |
| Amortization of premiums (discounts), net | -5,514 |
| Accounts receivable | 0 |
| Inventory | 0 |
| Operating leases, net | 15,157 |
| Other assets | 15,449 |
| Accounts payable | -625 |
| Accrued expenses | -5,785 |
| Net cash used in operating activities | -208,511 |
| Purchases of investments | 285,012 |
| Maturities of investments | 284,683 |
| Proceeds (payments) relating to the sale of the huntsville manufacturing facility, net | -697 |
| Purchases of property, plant and equipment | 171 |
| Net cash provided by (used in) investing activities | -1,197 |
| Proceeds from offering, net-Two Thousand Twenty Five Secondary Public Offering | 108,100 |
| Proceeds from offering, net-At The Market Offerings | 72,750 |
| Payments of offering costs associated with issuance of common stock | 1,150 |
| Proceeds from issuance of tcg pre-funded warrant | 0 |
| Proceeds from sale of future royalties | 0 |
| Repurchase of common stock from bristol-myers squibb | 0 |
| Proceeds from shares issued under equity compensation plans and tcg pre-funded warrant | 866 |
| Net cash provided by financing activities | 180,566 |
| Effect of foreign exchange rates on cash and cash equivalents | 6 |
| Net increase (decrease) in cash and cash equivalents | -29,136 |
| Cash and cash equivalents at beginning of year | 44,252 |
| Cash and cash equivalents at end of year | 15,116 |
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)